Pfizer Inc. announced that a Phase 4 study assessing the efficacy and safety of Toviaz (fesoterodine fumarate) in patients with overactive bladder (OAB) met its primary endpoint.

The US Food and Drug Administration has approved Myrbetriq ( mirabegron ) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.